VivoSeq
Oncology

Adult T-Cell Leukemia/lymphoma

22

Pipeline Programs↗

2

Active Trials↗

14

Companies Involved↗

Adult T-Cell Leukemia/lymphoma is an emerging landscape with 22 programs across 14 companies. The most active players are Sanofi, Eastern Cooperative Oncology Group, Daiichi Sankyo. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

60/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1E

Eastern Cooperative Oncology Group

3 programs

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2A

Avyxa

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

15 of 20 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody210%Antibody–drug conjugate15%Protein / enzyme15%Cell therapy15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting2 · 29%
Terminated2 · 29%

Clinical Trials

Trial Activity

7 trials

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06698003·134 enrolled
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recruiting·—·Phase 1·NCT04848064·12 enrolled
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00061048·29 enrolled
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
Completed·AAIDS Malignancy Consortium·Phase 2·NCT00041327·19 enrolled
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT04102150·25 enrolled
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
Terminated·UUniversity of Miami·Phase 4·NCT00854581·13 enrolled
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Terminated·Novartis logoNovartis·Phase 2·NCT00699296·4 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)